Abstract:A crucial limitation in antifungal chemotherapy is the limited number of antifungal drugs currently available. Azole drugs represent the most commonly used chemotherapeutic, and loss of efficacy of these drugs is a major risk factor in successful treatment of a variety of fungal diseases. Candida glabrata is a pathogenic yeast that is increasingly found associated with bloodstream infections, a finding likely contributed to by its proclivity to develop azole drug resistance. C. glabrata often acquires azole resistance via gain-of-function (GOF) mutations in the transcription factor Pdr1. These GOF forms of Pdr1 drive elevated expression of target genes, including the ATP-binding cassette transporter-encoding CDR1 locus. GOF alleles of PDR1 have been extensively studied, but little is known of how Pdr1 is normally regulated. Here we test the idea that reduction of ergosterol biosynthesis (as occurs in the presence of azole drugs) might trigger activation of Pdr1 function. Using two different means of genetically inhibiting ergosterol biosynthesis, we demonstrated that Pdr1 activity and target gene expression are elevated in the absence of azole drug. Blocks at different points in the ergosterol pathway lead to Pdr1 activation as well as to induction of other genes in this pathway. Delivery of the signal from the ergosterol pathway to Pdr1 involves the transcription factor Upc2A, an ERG gene regulator. We show that Upc2A binds directly to the PDR1 and CDR1 promoters. Our studies argue for a physiological link between ergosterol biosynthesis and Pdr1-dependent gene regulation that is not restricted to efflux of azole drugs. IMPORTANCE A likely contributor to the increased incidence of non- albicans candidemias involving Candida glabrata is the ease with which this yeast acquires azole resistance, in large part due to induction of the ATP-binding cassette transporter-encoding gene CDR1 . Azole drugs lead to induction of Pdr1 transactivation, with a central model being that this factor binds these drugs directly. Here we provide evidence that Pdr1 is activated without azole drugs by the use of genetic means to inhibit expression of azole drug target-encoding gene ERG11 . These acute reductions in Erg11 levels lead to elevated Pdr1 activity even though no drug is present. A key transcriptional regulator of the ERG pathway, Upc2A, is shown to directly bind to the PDR1 and CDR1 promoters. We interpret these data as support for the view that Pdr1 function is responsive to ergosterol biosynthesis and suggest that this connection reveals the normal physiological circuitry in which Pdr1 participates.

Amino terminus Flag tagging on Pdr1 in Candida glabrata

Sequence Modification of the Master Regulator Pdr1 Interferes with Its Transcriptional Autoregulation and Confers Altered Azole Resistance in Candida Glabrata

Mutation of P927S in PRD1 gene mediates azole resistance in Candida glabrata

Mutations of Charged Amino Acids at the Cytoplasmic End of Transmembrane Helix 2 Affect Transport Activity of the Budding Yeast Multidrug Resistance Protein Pdr5p.

CgPDR1 Gain-of-function Mutations Lead to Azole-Resistance and Increased Adhesion in Clinical Candida Glabrata Strains

Similarities and distinctions in the activation of the Candida glabrata Pdr1 regulatory pathway by azole and non-azole drugs

A Gain-of-function Mutation in PDR1 of Candida Glabrata Decreases EPA1 Expression and Attenuates Adherence to Epithelial Cells Through Enhancing Recruitment of the Mediator Subunit Gal11A.

Overlapping coactivator function is required for transcriptional activation by the Candida glabrata Pdr1 transcription factor

Similarities and distinctions in the activation of the Pdr1 regulatory pathway by azole and non-azole drugs

Redefining pleiotropic drug resistance in a pathogenic yeast: Pdr1 functions as a sensor of cellular stresses in Candida glabrata

Induction of Fluconazole Resistance in Candida Glabrata and Candida Parapsilosis in Vitro and Corresponding Mechanism

Mechanisms of Fluconazole Resistance in Clinical and Experimental Induced Isolates of Candida Glabrata

Genome‐wide profiling of piggyBac transposon insertion mutants reveals loss of the F1F0 ATPase complex causes fluconazole resistance in Candida glabrata

[Cloning and Sequencing of the GTP Cyclohydrolase I Function Region of Azole Target Enzyme Gene in Artificially Induced Resistant Candida Albicans].

Identification of Essential Genes and Fluconazole Susceptibility Genes in Candida glabrata by Profiling Hermes Transposon Insertions

ERG11 mutations and expression of resistance genes in fluconazole-resistant Candida albicans isolates

Evidence that Ergosterol Biosynthesis Modulates Activity of the Pdr1 Transcription Factor in Candida glabrata

[Molecular Mechanisms of Fluconazole Resistance in Clinical Isolates of Candida Glabrata].

Purification and characterization of Cdr1, the drug-efflux pump conferring azole resistance in Candida species

Study on mechanisms of zole-resistance of clinical Candida glabrata isolates

RTA2, a novel gene involved in azole resistance in Candida albicans.